Welcome to GMP

Launched in 2024, UCI’s state-of-the-art GMP facility was established to produce FDA-compliant cell and gene therapies. It is uniquely poised to specialize in the production of cell and gene therapies for clinical trials in neurological diseases and cancer, significantly expanding treatment options for our patients and positioning UCI at the forefront of pioneering novel regenerative treatments into clinical practice. The approximately 7,700 square foot GMP facility is located in the basement of Hewitt Research Hall with a manufacturing space, a storage warehouse for raw and finished products, and support laboratory areas, including space for quality control testing. It is a multi-use facility with 7 separate manufacturing rooms, designed to operate at Biosafety Level 2 (BSL-2) serving both internal and external clients.